In Silico Design of Polymeric Antidote for Anticoagulant Fondaparinux
暂无分享,去创建一个
Bhushan Gopaluni | Ezra Kwok | Adriana Cajiao | Jayachandran N. Kizhakkedathu | Bhushan Gopaluni | E. Kwok | J. Kizhakkedathu | Adriana Cajiao
[1] Robert J. Linhardt,et al. Heparin—Protein Interactions , 2002 .
[2] S Alban,et al. From heparins to factor Xa inhibitors and beyond , 2005, European journal of clinical investigation.
[3] S. Schulman,et al. Anticoagulants and their reversal. , 2007, Transfusion medicine reviews.
[4] J. Th. G. Overbeek,et al. The electrical Duoble Layer and the Theory of Electrophoresis , 1978 .
[5] J. Ferguson,et al. Low-Molecular-Weight Heparins , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[6] Souvik Maiti,et al. Blood compatibility of novel water soluble hyperbranched polyglycerol-based multivalent cationic polymers and their interaction with DNA. , 2006, Biomaterials.
[7] Elaine Gray,et al. Heparin and low-molecular-weight heparin , 2008, Thrombosis and Haemostasis.
[8] Brian K Adler,et al. Unfractionated Heparin and Other Antithrombin Mediated Anticoagulants , 2004, American Society for Clinical Laboratory Science.
[9] J. Weitz,et al. Emerging anticoagulants for the treatment of venous thromboembolism , 2006, Thrombosis and Haemostasis.
[10] J. Weitz. Low-molecular-weight heparins. , 1997, The New England journal of medicine.
[11] J. Weitz,et al. New anticoagulants , 2005, Journal of thrombosis and haemostasis : JTH.
[12] Gideon Schreiber,et al. New insights into the mechanism of protein–protein association , 2001, Proteins.
[13] M. D. Freedman,et al. Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin , 1992, Journal of clinical pharmacology.
[14] J. Aqvist,et al. A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.
[15] Roderick E. Hubbard,et al. 3D structure and the drug-discovery process , 2005 .
[16] J Ingerslev,et al. Use of recombinant factor VIIa for emergency reversal of anticoagulation. , 2007, Journal of postgraduate medicine.
[17] Yaroslav Filinchuk,et al. A flexible tripodal ligand linking octametallic terbium rings into luminescent polymeric chains. , 2008, Chemical communications.
[18] G Schreiber,et al. Predicting the rate enhancement of protein complex formation from the electrostatic energy of interaction. , 1999, Journal of molecular biology.
[19] P. V. von Hippel,et al. Diffusion-controlled macromolecular interactions. , 1985, Annual review of biophysics and biophysical chemistry.
[20] Patrick F. Fogarty,et al. Diagnosis and management of venous thromboembolism. , 2008, The Medical clinics of North America.
[21] M Sobel,et al. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes. , 1996, Archives of biochemistry and biophysics.
[22] J. Weitz,et al. Beyond heparin and warfarin: the new generation of anticoagulants , 2007, Expert opinion on investigational drugs.
[23] Gideon Schreiber,et al. Fundamental Aspects of Protein—Protein Association Kinetics , 2009 .
[24] Gideon Schreiber,et al. Rational design of faster associating and tighter binding protein complexes , 2000, Nature Structural Biology.
[25] Jeffrey I. Weitz,et al. Emerging Anticoagulant Drugs , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[26] Kenichi A Tanaka,et al. The anticoagulated patient: strategies for effective blood loss management. , 2007, Surgery.